Serina Therapeutics Appoints New CMO, Director
Ticker: SER · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: personnel-change, board-appointment, executive-appointment
TL;DR
Serina Therapeutics just hired a new CMO and added a director to the board. Big changes coming?
AI Summary
Serina Therapeutics, Inc. announced on July 15, 2024, the appointment of Dr. David E. Smith as Chief Medical Officer and the election of Ms. Sarah E. Johnson to its Board of Directors. The company also disclosed compensatory arrangements for its officers. This filing follows a name change from AgeX Therapeutics, Inc. on June 6, 2017.
Why It Matters
The appointment of a new Chief Medical Officer and a board member can signal strategic shifts or new directions for the company's research and development efforts.
Risk Assessment
Risk Level: low — This filing primarily concerns personnel changes and does not involve significant financial transactions or operational disruptions.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- Dr. David E. Smith (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Johnson (person) — Elected to Board of Directors
- AgeX Therapeutics, Inc. (company) — Former Company Name
- July 15, 2024 (date) — Date of earliest event reported
- June 6, 2017 (date) — Date of name change
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. David E. Smith has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Sarah E. Johnson has been elected to the Board of Directors.
What was Serina Therapeutics, Inc. formerly known as?
Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc.
When did the company change its name?
The company changed its name on June 6, 2017.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is July 15, 2024.
Filing Stats: 602 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-07-18 17:06:39
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SER NYSE American Indic
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- 0001493152-24-028363.txt ( ) — 254KB
- ser-20240715.xsd (EX-101.SCH) — 3KB
- ser-20240715_lab.xml (EX-101.LAB) — 33KB
- ser-20240715_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: July 18, 2024 By: /s/ Steven Ledger Interim Chief Executive Officer